Sabby Management’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-2,350
Closed -$2.84M 130
2018
Q3
$2.84M Buy
2,350
+1,904
+427% +$26.6K 0.36% 38
2018
Q2
$697K Sell
446
-559
-56% -$8.45K 0.11% 73
2018
Q1
$1.51M Sell
1,005
-9,366
-90% -$143K 0.18% 47
2017
Q4
$14.9M Buy
10,371
+6,233
+151% +$85.6K 1.36% 13
2017
Q3
$6.24M Sell
4,138
-820
-17% -$10.8K 0.41% 33
2017
Q2
$4.99M Buy
4,958
+605
+14% +$4.87K 0.33% 38
2017
Q1
$3.1M Sell
4,353
-5,863
-57% -$37.1K 0.17% 66
2016
Q4
$5.08M Buy
10,216
+584
+6% +$4.04K 0.3% 51
2016
Q3
$7.13M Buy
9,632
+1,640
+21% +$11.1K 0.27% 58
2016
Q2
$4.36M Buy
7,992
+5,587
+232% +$39.1K 0.23% 58
2016
Q1
$2.03M Buy
2,405
+668
+38% +$4.73K 0.1% 98
2015
Q4
$1.69M Buy
1,737
+1,007
+138% +$9.07K 0.09% 141
2015
Q3
$1.02M Buy
730
+97
+15% +$1.52K 0.04% 232
2015
Q2
$896K Sell
633
-1,151
-65% -$13.8K 0.03% 223
2015
Q1
$1.94M Buy
1,784
+1,238
+227% +$10.9K 0.08% 148
2014
Q4
$454 Buy
+546
New +$3.75K 0.01% 190

Other funds holding FOLD

Sabby Management's FOLD Position: Q4 2018 in Review

Sabby Management sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 155,044 shares — an estimated $1.87M sold.

Sabby Management first reported a position in FOLD in Q2 2014 and held it in 9 quarters. The position peaked at $1.87M in Q3 2018. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Sabby Management reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Sabby Management sold 155,044 Amicus Therapeutics shares in Q4 2018, an estimated $1.87M.
  • Sabby Management first reported a position in Amicus Therapeutics in Q2 2014 and held it in 9 quarters.
  • Sabby Management's Amicus Therapeutics position peaked at $1.87M in Q3 2018.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.